ClinicalTrials.gg
RecruitingNCT07864220Updated Oct 7, 2026

Periodontal Pathogens and Inflammatory Biomarkers in Missed Abortion

An observational study in Missed Abortion and Periodontitis, sponsored by Necmettin Erbakan University. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Necmettin Erbakan University · Observational

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
160
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

This observational case-control study will investigate whether periodontal infection and inflammation are associated with missed abortion in pregnancies without detected major fetal chromosomal abnormalities.

A total of 160 pregnant women aged 18 to 40 years and at 20 weeks of gestation or earlier are planned to be enrolled. The study will include 80 women diagnosed with missed abortion and 80 women with an ongoing uncomplicated pregnancy matched according to age and gestational week.

Participants will undergo a clinical periodontal examination, and unstimulated saliva samples will be collected. Saliva will be analyzed for selected periodontal bacteria, including Porphyromonas gingivalis, Fusobacterium nucleatum, and Tannerella forsythia, as well as inflammatory biomarkers.

Serum obtained from blood samples already collected as part of routine obstetric care will be used to measure inflammatory biomarkers, including IL-1β, IL-6, TNF-α, CRP, MMP-8, and prostaglandin E2. No additional blood sample will be collected solely for this study. Routine complete blood count results will also be used to calculate systemic inflammatory indices.

For participants with missed abortion, study samples and periodontal assessments will be obtained after the diagnosis has been confirmed and before uterine evacuation or medical treatment. Routine fetal genetic test results will be reviewed, and cases with detected chromosomal abnormalities included in the clinical genetic assessment will be excluded from the main analysis.

The study aims to determine whether periodontal pathogen burden, periodontal disease, and local and systemic inflammatory responses differ between women with missed abortion and women with ongoing uncomplicated pregnancies.

Read the detailed description

This is a prospective, matched case-control observational study conducted at Necmettin Erbakan University. The study population will consist of pregnant women followed at the Department of Obstetrics and Gynecology. Participants will be enrolled after providing written informed consent.

The study is planned to include 160 participants: 80 pregnant women diagnosed with missed abortion and 80 pregnant women with an ongoing uncomplicated pregnancy. Control participants will be matched to cases according to age within approximately 2 years and gestational age within approximately 1 week.

Women aged 18 to 40 years at 20 weeks of gestation or earlier will be eligible. Participants with detected fetal chromosomal or genetic abnormalities, current smoking or alcohol use, diabetes mellitus, hypertension, autoimmune disease, antibiotic use within the previous 3 months, induced abortion, or multiple pregnancy will be excluded.

For the missed abortion group, saliva sampling and periodontal examination will be performed after the diagnosis of missed abortion has been confirmed and before uterine evacuation, curettage, or medical treatment. For the control group, saliva samples and periodontal measurements will be obtained during routine pregnancy follow-up.

Unstimulated whole saliva will be collected before periodontal examination to minimize contamination related to probing-induced bleeding. Salivary periodontal pathogen burden will be evaluated using quantitative real-time polymerase chain reaction. The target microorganisms will include Porphyromonas gingivalis, Fusobacterium nucleatum, and Tannerella forsythia. Salivary concentrations of IL-1β, IL-6, TNF-α, MMP-8, and prostaglandin E2 will also be assessed using validated immunoassay methods.

Serum samples will be obtained only from residual blood remaining after routine clinically indicated obstetric laboratory testing. No additional venous blood collection will be performed solely for research purposes. Serum levels of CRP, IL-1β, IL-6, TNF-α, MMP-8, and prostaglandin E2 will be evaluated.

Routine complete blood count parameters will also be recorded. These data will be used to calculate systemic inflammatory indices, including the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, mean platelet volume-to-platelet ratio, and systemic immune-inflammation index.

A comprehensive periodontal examination will be performed, including probing pocket depth, clinical attachment level, bleeding on probing, gingival index, plaque index, gingival recession, tooth mobility, furcation involvement, and missing tooth status.

In the missed abortion group, routine genetic examination results from abortus material will be reviewed. Genetic assessment performed as part of routine clinical care includes evaluation of selected autosomal chromosomes and sex chromosomes using qPCR/QF-PCR and STR-based methods, together with assessment for maternal cell contamination. Cases with detected fetal chromosomal abnormalities or unreliable fetal genetic results will not be included in the main analysis.

Participants in the control group will be followed through routine obstetric records to verify continuation of pregnancy through at least 20 weeks of gestation and, when feasible, through 24 weeks. Participants who develop missed abortion, spontaneous abortion, detected fetal chromosomal abnormality, or a major obstetric complication before the predefined confirmation point will be excluded from the control-group analysis.

The primary objective is to assess the relationship between periodontal infection and missed abortion after exclusion of detected major fetal chromosomal abnormalities. Additional objectives are to compare local and systemic inflammatory biomarkers between groups and to investigate associations among periodontal pathogen burden, periodontal clinical status, inflammatory mediators, and prostaglandin E2.

02

Conditions studied

  • Missed Abortion
  • Periodontitis

Keywords

  • Missed abortion
  • Periodontitis
  • Pregnancy loss
  • Pregnancy
03

In context

Abortion, Missed

48 studies on the registry are indexed under Abortion, Missed; 10 are open to participants now.

Browse Abortion, Missed studies →

Lead sponsor

Necmettin Erbakan University is the lead sponsor of 201 studies on the registry; 46 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will consist of pregnant women aged 18-40 years at 20 weeks of gestation or earlier who are followed at the Department of Obstetrics and Gynecology, Necmettin Erbakan University. The case group will include women diagnosed with missed abortion who meet the eligibility criteria and have no detected fetal chromosomal abnormalities based on the available routine genetic evaluation. The control group will include women with an ongoing uncomplicated pregnancy and will be matched to cases according to age (±2 years) and gestational age (±1 week).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants aged 18-40 years Pregnancy at 20 weeks of gestation or earlier For the case group: diagnosis of missed abortion For the control group: ongoing uncomplicated pregnancy Provision of written

Exclusion criteria

Exclusion Criteria:

  • Detected fetal chromosomal or genetic abnormality Current smoking Alcohol use Diabetes mellitus Hypertension disease Antibiotic use within the previous 3 months Induced abortion Multiple pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
160 participants (estimated)
Patient registry
No

Groups and cohorts

  • Missed Abortion Group

    Pregnant women aged 18-40 years at 20 weeks of gestation or earlier who are diagnosed with missed abortion and meet the study eligibility criteria. Cases with detected fetal chromosomal abnormalities or unreliable fetal genetic results will be excluded from the main analysis. Study assessments will be performed after confirmation of missed abortion and before uterine evacuation, curettage, or medical treatment.

  • Healthy Pregnancy Control Group

    Pregnant women aged 18-40 years with an ongoing uncomplicated pregnancy at 20 weeks of gestation or earlier. Control participants will be matched to participants in the missed abortion group according to age (±2 years) and gestational age (±1 week). Pregnancy continuation will be verified through at least 20 weeks of gestation and, when feasible, through 24 weeks.

06

What researchers measure

Primary outcomes

  1. Salivary Porphyromonas gingivalis Burden

    Porphyromonas gingivalis burden in unstimulated whole saliva will be quantitatively assessed using real-time polymerase chain reaction (qPCR). Bacterial burden will be reported using the quantitative output of the assay, such as bacterial copy number or bacterial load normalized to total bacterial load.

    Time frame: Baseline

  2. Salivary Fusobacterium nucleatum Burden

    Fusobacterium nucleatum burden in unstimulated whole saliva will be quantitatively assessed using real-time polymerase chain reaction (qPCR). Bacterial burden will be reported using the quantitative output of the assay, such as bacterial copy number or bacterial load normalized to total bacterial load.

    Time frame: Baseline

  3. Salivary Tannerella forsythia Burden

    Tannerella forsythia burden in unstimulated whole saliva will be quantitatively assessed using real-time polymerase chain reaction (qPCR). Bacterial burden will be reported using the quantitative output of the assay, such as bacterial copy number or bacterial load normalized to total bacterial load.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Feb 2027, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2026
First posted
Oct 7, 2026
StartActual
Aug 1, 2026
Primary completionEst.
Feb 15, 2027
CompletionEst.
Jun 15, 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07864220
Responsible party
Osman Babayigit (Associate Professor, Necmettin Erbakan University) — Principal investigator
First posted
Oct 7, 2026
Start date
Aug 1, 2026
Primary completion
Feb 15, 2027 (estimated)
Completion
Jun 15, 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Osman Babayiğit
Contact
obabayigit@erbakan.edu.tr
+905063208474

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion